Aldeyra Therapeutics, Inc. (ALDX) financial statements and ratios from SEC XBRL: revenue $3.32M (TTM), net margin -1018.3%, revenue growth -54.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $3.32M |
| Net Margin | -1018.3% |
| Revenue Growth (YoY) | -54.1% |
| EPS Growth (YoY) | -43.8% |
| Price / Book | 2.42 |
| Price / Sales | 37.68 |
| Altman Z-Score | -8.27 (distress) |
| Sector P/E (Healthcare) | 21.7 |
ALDX overview · ALDX earnings · ALDX KPIs · ALDX investor relations · ALDX ownership · ALDX peers · ALDX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.